It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
AI Meets Expertise: A hybrid Workflow For Modern Target ID | QIAGEN & Sygnature
In drug discovery, generating targets is no longer the challenge.
The real question is how to identify the few worth investing months of research and significant resources to pursue.
Hear expert perspectives on how AI, pathway analysis and scientific expertise are shaping modern target identification.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Explore our high-throughput GPCR assays with Montana Molecular biosensors. Illuminate GPCR signaling in live cells with green/red biosensors for kinetic and endpoint responses. Tailored for cutting-edge drug discovery. Download findings now!
Discover CHARMED, Sygnature’s innovative PROTAC platform, showcasing rapid degrader identification demonstrated with SHP2 as a model oncology target. Explore our advancements in protein degradation.
Explore the world of microglia in our study, revealing a model for understanding their role in neurodegenerative diseases and potential therapies. Join us in navigating the future of treatment for neurological disorders.
Explore cytokine dynamics in inflammation with our insightful poster, featuring advanced quantification techniques. Download for invaluable insights in immunology and drug discovery.
Explore our rodent model mimicking human glomerulonephritis for preclinical testing of autoimmune kidney disease therapies. Uncover rapid onset kidney damage, inflammation, and fibrosis within 24 hours.
The study investigates the preventative effects of dexamethasone on lipopolysaccharide (LPS)-induced neuroinflammation. Neuroinflammation is associated…
Our comprehensive selection of in vitro microglia models, including rat embryonic and adult primary microglia and human monocyte-derived microglia, allows us to provide invaluable tools for screening campaigns aimed at identifying novel drug targets and therapies for neuroinflammatory conditions.
Our study delves into the influence of implantation sites on syngeneic breast cancer models. We uncovered that the choice of site significantly impacts tumor growth, viability, and immune cell composition. Notably, the MFP9 site showed the best outcomes in both 4T1 and EO771 models. This research highlights the importance of considering implantation sites when assessing therapeutics with diverse mechanisms of action.
Explore our study on the synergy between immune checkpoint inhibitors and radiotherapy in treating colorectal cancer. We found that this combination significantly boosts efficacy, with flow cytometry revealing insightful changes in the tumor microenvironment. Our research opens the door to improved cancer therapies, offering a platform for testing new drugs and novel treatment approaches.
In a study assessing the effects of dexamethasone, enalaprilat, and SB525334 on kidney slices from adriamycin-exposed mice, it was found that dexamethasone and enalaprilat effectively reduced inflammation and, in dexamethasone’s case, mitigated fibrosis. These findings emphasize the importance of inflammation in adriamycin-induced nephropathy and the value of precision-cut kidney slices as a platform for evaluating anti-inflammatory and anti-fibrotic therapies.
